Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet medical needs, particularly within urology and related inflammatory conditions. The company’s core mission is to advance novel drug formulations and delivery approaches aimed at improving outcomes in chronic and difficult-to-treat disorders of the bladder and urinary tract. As a development-stage enterprise, Lipella does not generate commercial product revenue and is primarily funded through equity financing and public market activity.
The company’s lead development efforts center on treatments for hemorrhagic cystitis and interstitial cystitis/bladder pain syndrome (IC/BPS), conditions for which approved therapeutic options are limited. Lipella’s strategy emphasizes reformulation of known active pharmaceutical ingredients using proprietary delivery technologies to enhance efficacy and safety. The company was founded in 2005, later transitioning into a publicly traded entity following its initial public offering in 2021, which provided capital to advance its clinical pipeline.
Business Operations
Lipella Pharmaceuticals operates as a single-segment clinical-stage biotechnology company, with all activities aligned under its drug development and clinical research operations. The company’s primary revenue-related activities are limited to financing transactions, as it has no approved products for sale. Research and development expenditures are focused on advancing clinical trials, regulatory engagement, and formulation development.
The company’s lead product candidate, LP-10, is an orally administered liposomal formulation of tacrolimus designed to target inflammatory bladder conditions while minimizing systemic exposure. Lipella conducts its development activities primarily through third-party clinical research organizations, manufacturing partners, and academic collaborators. Based on available public disclosures, the company does not report material subsidiaries or joint ventures, and its operations are largely centralized within the United States.
Strategic Position & Investments
Lipella’s strategic direction is centered on advancing LP-10 through clinical development and expanding its pipeline within urologic and inflammatory disease indications. The company prioritizes orphan and niche indications where smaller, well-designed clinical trials may support regulatory pathways. Its strategy also includes evaluating additional indications for its delivery platform where existing drugs may benefit from localized or targeted administration.
The company has not disclosed any major acquisitions or equity investments in other operating businesses. Instead, capital allocation has been focused on internal research and development, intellectual property protection, and regulatory preparation. Public disclosures indicate that Lipella remains in an early clinical phase, and information regarding additional pipeline candidates beyond LP-10 is limited; data inconclusive based on available public sources.
Geographic Footprint
Lipella Pharmaceuticals is headquartered in the United States, with corporate offices and management functions located domestically. Its operational footprint is primarily U.S.-based, reflecting its status as a small clinical-stage biotechnology firm.
Clinical development activities may involve trial sites across North America, depending on study design and patient recruitment needs. The company does not report commercial operations or owned facilities outside the United States, and there is no verified evidence of direct international subsidiaries or manufacturing assets as of the most recent public disclosures.
Leadership & Governance
Lipella is led by a management team with experience in biotechnology, clinical medicine, and pharmaceutical development. Leadership emphasizes capital discipline, focused clinical execution, and targeting underserved patient populations through differentiated drug delivery approaches. Corporate governance is overseen by a board of directors consistent with public company requirements.
Key executives include:
- Jonathan S. Kaufman, MD – Chief Executive Officer and Chairman
- Michael King – Chief Financial Officer
- Brian Johnston – Chief Operating Officer
Information regarding additional executive officers or recent leadership changes is limited in publicly available filings; data inconclusive based on available public sources.